Nanocarriers breach blood-brain barrier to deliver anti-inflammatory medicine

An enzyme-based system for extraction of small extracellular vesicles from plants

Plant-derived nanovesicles (NVs) and extracellular vesicles (EVs) are the next generation of nanocarrier platforms for biotherapeutics and drug delivery. EVs exist not only in the extracellular space, but also within the cell wall. Due to the limitations of existing isolation methods, the EVs extraction efficiency is low, and a large amount of plant material is wasted, which is of concern for rare and expensive medicinal plants. We proposed and …

Nanocarriers breach blood-brain barrier to deliver anti-inflammatory medicine

Oregon State University researchers have discovered a way to get anti-inflammatory medicine across the blood-brain barrier, opening the door to potential new therapies for a range of conditions, including Alzheimer's disease, multiple sclerosis, Parkinson's disease and cancer cachexia.

Breakthrough nanoparticle delivery method targets brain inflammation for multiple conditions

Oregon State University researchers have discovered a way to get anti-inflammatory medicine across the blood-brain barrier, opening the door to potential new therapies for a range of conditions, including Alzheimer's disease, multiple sclerosis, Parkinson's disease and cancer cachexia.

GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier

GSK is licensing an ABL Bio technology that yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease. The post GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier appeared first on MedCity News.

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting

GSK targets neurodegenerative diseases with latest licensing deal

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.